More News
5 November 2018
MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan2 November 2018
BioArctic’s partner AbbVie exercises its option to license the alpha-synuclein antibody portfolio for Parkinson’s Disease2 November 2018
Embark and Novo Nordisk enter collaboration to discover novel therapeutics for obesity and metabolic disease1 November 2018
Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases31 October 2018
Gilead Sciences and Tango Therapeutics Announce Strategic Collaboration to Develop Next-Generation Targeted Immuno-Oncology Therapies31 October 2018
Strongbridge Biopharma plc Enters into Agreement for Novo Nordisk to Acquire the U.S. and Canadian Rights to MACRILEN™ (macimorelin)31 October 2018
Halozyme Licenses New ENHANZE® Targets For $25 Million Upfront Payment, Future Milestones And Royalties30 October 2018
Oblato acquires all rights to glioblastoma drug from OMRF26 October 2018
AbbVie to Assume Full Development and Commercial Control of Cystic Fibrosis Research Program26 October 2018
Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases24 October 2018
Zymeworks and LEO Pharma Enter into Bispecific Antibody Licensing and Research Collaboration24 October 2018
IDEAYA Licenses Phase 1 Compound LXS196 For The Treatment Of Cancers With GNAQ And GNA11 Mutations23 October 2018
Neos Therapeutics Licenses Pipeline Candidate for Treatment of Sialorrhea (Excessive Drooling)23 October 2018
Enterome Signs Global Licensing, Co-development and Co-promotion Agreement with Takeda for the Treatment of Crohn’s Disease23 October 2018
REGENXBIO Announces Exclusive Worldwide License with Ultragenyx for the Treatment of CDKL5 Deficiency Disorder Using NAV Vectors23 October 2018
AstraZeneca strengthens and expands oncology development and commercialisation collaboration with Innate Pharma22 October 2018
Anaeropharma Science Signs Collaborative Research Agreement with Chugai on Creation of Novel Oncology Drugs Using BifidobacteriumNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports